Although our knowledge of the underlying genetic causes of acute myeloid leukemia (AML) and their consequent molecular results has progressed drastically over the past decade, there is still much to learn. In this interview, Mark Levis, MD, PhD, of Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses his highlights in this regard from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA. Speaking from the meeting, Dr Levis highlights abstracts investigating how DNMT3 mutations work and follow-up data from the RATIFY study of midostaurin (NCT00651261).
Molecular genetics and targeting in AML: highlights from ASH 2017
